Objectives, To evaluate clinical and urodynamic changes in patients with and without bladder outlet obstruc tion [BOO] and to compare the. clinical and urodynamic results of terazosin treatment between patients with and without BOO. Methods, In a prospective study, 97 patients who completed a full screening program including urodynamic investigation with pressure-flow study analysis started treatment with terazosin. A total of 60 patients com pleted 6 months of treatment and were re-evaluated with International Prostate Symptom Scores (IPSS), uroflowmetry, and urodynamic investigation with pressure-flow study analysis. Patients were stratified using the linear passive urethral resistance relation (lin-PURR) classification according to Sdhafer. Patients with a !in-PURR of 3 or more were classified as patients with BOO and patients with a lin-PURR of 2 or less were classified as patients without BOO. The clinical and urodynamic changes within and between the groups with and without BOO were evaluated. Results. Terazosin resulted in significant symptomatic relief (9 points on the IPSS scale; P <0.01) and a significant improvement of free urinary flow (3.0 mL/s; P <0.01). In patients with BOO, a statistically signif icant improvement of all urodynamic obstruction variables (P <0.01) was shown. In patients without BOO, a significant improvement of free urinary flow (4.4 mL/s; P <0.01), a statistically significantly improved bladder capacity (increase of 70 mL; P = 0.01), and no statistically significant changes in urodynamic ob struction variables (P >0.05) were shown. Patients with a hypoactive detrusor were more prone to early dropout. When comparing the changes of symptoms (P = 0.89), quality of life (P = 0.85), and the number of patients with improvements of free uroflow of at least 30% (P = 0.15), there appeared to be no significant difference between the groups with and without BOO. Conclusions. Although there is a statistically significant difference in urodynamic response to terazosin treat ment between patients with and without BOO, we cannot recommend the use of pressure-flow studies in the selection of patients for terazosin treatment because the clinical results of treatment appear not to be sig nificantly different between patients with and without BOO. It seems more useful, and certainly less expensive and less invasive, to start alpha^blocker therapy if, on clinical grounds, the urologist considers the patient to be a candidate for alphar blocker therapy, and to continue therapy in those who respond. Copyright 1997 by Elsevier Science Inc. UROLOGY 49: 197-206, 1997. L ower urinary tract symptoms (LUTS) in elderly men are traditionally labeled as prostatism. The term suggests that the enlarged prostate gland,
causing infravesical bladder outlet obstruction (BOO), is exclusively responsible for the LUTS. However, benign prostatic hyperplasia (BPH) is a histologic diagnosis, and LUTS are not necessarily related to urodynamically proven BOO or histo logically proven BPH.1,2 LUTS have been shown to be prevalent in an age-matched female population, indicating that the prostate is not required for the occurrence of these symptoms. 3 It has also been recognized that LUTS are related to detrusor in stability or detrusor underactivity in a large per-centage of elderly men.4,5 Obviously, the patho physiology of LUTS is not always clear without an advanced urodynamic pressure-flow study inves tigation. Urodynamic pressure-flow study investi gation is the reference standard to quantify the grade of BOO in elderly men with LUTS. 6 Precise grading of obstruction is becoming increasingly important in the evaluation and comparison of new therapeutic options in the treatment of pa tients with LUTS.
Because it is known that alphai-adrenoreceptors are predominantly present in the bladder neck and prostate smooth muscle, alphai-blocking agents have successfully been used to relieve symptoms in patients with LUTS,7"9 Terazosin is a long-act ing alphar selective blocking agent originally used in the treatment of patients with hypertension. The effects of terazosin on symptom scores and urinary flow rates in large groups of patients with LUTS have been well documented. 8, 9 These studies indicate that approximately 60% of patients re spond well on treatment with terazosin. So far, it is unknown if it is possible to predict a good re sponse on alphar blocker treatment in the individ ual patient. Consequently, selection of patients who should be treated with an alphai-blocker or one of the other treatment modalities is still not based on scientific grounds. Earlier studies indi cated that inclusion of urodynamic pressure-flow data in the preoperative evaluation may improve the overall clinical results, as does an indication for transurethral resection of the prostate.5,10,11 Jensen11 showed that symptomatic patients with out BOO have a higher likelihood of subjective postoperative treatment failure when compared with symptomatic patients with BOO. It is un known if a stratification based on the grade of BOO has any predictive value for patients who are treated with an alphai-selective blocking agent. In our study, we investigated possible differences in treatment outcome between patients with and pa tients without BOO who were treated with tera zosin.
PATIENTS AND METHODS
Id 1992, we started a prospective study to evaluate the out come of therapy in patients with LUTS treated with terazosin. Between September 1992 and October 1994, all patients were evaluated at baseline by medical history, International Pros tate Symptom Score (IPSS), prostate-specific antigen analysis, physical examination including digital rectal examination, ul trasonographic examination of the prostate, and free urinary flowmetry with subsequent ultrasonographic measurement of residual urinary volume. Prostate-specific antigen was deter mined using the Tandem-E PSA assay (Hybritech, San Diego, Calif). Prostate volume was calculated using the planimetric method with a Kretz Combison 330 ultrasound scanner and a multiplane 3-D rectal transducer (VRW 177AK). For free urinary flowmetry, the Dantec Urodyn 1000 flowmeter was used. For evaluation of the voiding efficiency, the voided per centage (the relative amount of bladder contents that was ex pelled during micturition), was calculated. All patients were considered neurologically normal, based on history, symp toms, and physical examination (no motor, sensory or reflex deficits). Patients in whom a prostatic carcinoma or other dis ease beyond the prostate could be expected, which could pos sibly influence their LUTS (for example, urethral stricture or bladder neck contracture), were evaluated more extensively first (by prostate biopsy or urethrocystoscopy) and excluded if these diseases were confirmed. Excluded were patients pre viously treated with transurethral (laser) resection of the pros tate, transurethral microwave thermo therapy, or 5alpha-reductase inhibitors. Patients treated with alpha-blockers within 4 weeks before the baseline pressure-flow study was per formed were also excluded. There were no explicit urody namic pressure-flow study selection criteria. After the clinical diagnosis was established, patients were informed about the treatment options. When the patient experienced moderate symptoms or the patient was bothered by his symptoms, ter azosin treatment was recommended in addition to other min imally invasive therapies. Patients started treatment with an increasing dose, to a maximum of 10 mg/day terazosin at 6 weeks of treatment, administered at bedtime. Every patient's dose was titrated up to 10 mg, but patients not tolerating the 10-mg dose had their dosage decreased to 5 mg. Urodynamic pressure-flow studies before and after 6 months of treatment with terazosin were used to evaluate urodynamic changes. Urinalysis and culture were negative at the time of pressureflow studies. After 6 months of treatment, patients were reevaluated both clinically and urodynamically.
Urodynamic pressure-flow studies were performed with an 8F transurethral lumen catheter equipped with an intravesical micro tip pressure sensor for bladder-pressure recording. Ab dominal pressure was recorded intrarectally with an 8F mi crotip sensor catheter (MTC, Drager, Best, Netherlands). Be fore cystometry, the bladder was emptied through the lumen of the transurethral catheter. The bladder was filled with 20°C water at a rate of 50 mL/min, with the patient in supine po sition. To ensure a reliable micturition diary, free uroflowmetry, and residual urine, care was taken to fill the bladder until the maximum bladder capacity was reached. Filling was stopped when the patient expressed a very strong urge to void. Commercially available equipment (UD 2000, MMS, En schede, Netherlands) was used to record the pressure and flow data. Digitally stored data were translated to a urodynamic analysis computer program developed at our own department. This program provides a half automatic pressure-flow study analysis with passive urethral resistance relation (PURR) and urethral resistance factor (URA).
To provide an objective and precise grading of obstruction, pressure-flow graphs were fitted with a PURR curve at the lowest pressure part of the graph. 12 The minimal urethral opening pressure during micturition (Pvoidmin) and theoreti cal cross-sectional urethral lumen (Atheo) were calculated au tomatically on the basis of these manually adjusted PURR curves,12 The pressure at maximum flow during the urody namic investigation (PdetQmax) was recorded. Correction for flow artifacts was performed when necessary. URA was deter mined by fitting the pressure-flow plot at the point of maxi mum flow (at P^Qmax). URA was used to classify patients on a continuous, one-parameter scale of obstruction. 13 We also added a nonparametric analysis of obstruction with clin ical classes according to the linear PURR (lin-PURR) pressureflow nomogram.14 The lin-PURR was determined by drawing a straight line between the PdctQmax and the Pvoidmin points on the pressure-flow curve. The position of this line defined the outlet condition in a simple way and allowed classification of the severity of BOO. The following urodynamic variables were analyzed from free flowmetry: free Qmax; free voided TA BLE I. Mean baseline characteristics of 9 7 patients included in the study (standard deviation in parentheses) * theoretical cross-sectional urethral lumen; BOO = bladder outlet obstruction; IPSS = J n ie m trtiijn a l Prostate Symptom Score; lin-PURR ~ linear passive uretheral resistance relation; P,tetQmax = detrusor pressure at maximum JIow; Pvoid"lin = mmiinal urethral opening pressure (hiring iniciiiriiion; Qmax = maximum Jloiv; URA = urethral resistance factor; urod Qmax = maximum flow during urodynamic mvesiigniicm; urod residual volume = residual vohanc after urodynamic pressurc-jlow study; urod voided percentage ~ voided percentage during pressure-jlow study. * P value indicates statistically signi/jcant difference (P <0.05) between the baseline characteristics of the groups with and without bladder outlet obatruction volume; residual volume after free flowmetry; and free voided percentage. Bladder capacity was analyzed from cystometry* Finally, the following were analyzed from pressure-flow study: maximum flow during urodynamic investigation (urod Qmax), PL lelQmax, Pvoidniin, Alheo, URA, residual volume after urodynamic pressure-ilow study (urod residual volume), and voided percentage during pressure-flow study (urod voided percentage) for the whole group of patients and for subgroups of patients who were categorized as patients with BOO (lin-PURR of 3 or more) and patients categorized as patients with out BOO (lin-PURR less than 3).15 All statistical tests were two-sided and carried out at the 5% significance level. For numerical variables (such as symp tom scores, quality-of-life scores, free flow parameters, and urodynamic parameters), within-treatment changes were as sessed using the paired £ test or the Wilcoxon matched-pairs signed-ranks test; between-treatment group changes were as sessed using the t test for independent samples or the Mann-Whitney U test. The number of patients with an increase of voided volume of 50 mL or greater and with an improvement of Qmax of 10% or more from baseline in the groups with and without BOO were compared using the chi-square test.
RESULTS
From September 1992 to October 1994, 97 pa tients started treatment with terazosin. The base line characteristics of 97 patients-and for sub groups with and without BOO-who were included in the study are indicated in Table I . This table indicates that patients without BOO had, in addition to significantly different urodynamic vari ables, a significant higher free Qmax and a signif icantly higher free voided percentage.
Twenty-eight patients (29%) stopped terazosin treatment before the evaluation at 6 months because of side effects (n = 13), no response to therapy (n = 12), or symptoms improving "spontaneously" (n = 3). The most frequent treat ment-related side effects were mild headache, diz ziness, and asthenia. Usually, these side effects were mild and transient. Of the 13 patients who experienced side effects, 9 stopped treatment be cause of treatment-related side effects: dizziness (n = 2), asthenia (n -4), palpitations (n = 1), pe ripheral edema (n = 1), and paresthesia (n = 1). Dyspnea (n = 2), cardiac arrhythmia (n = 1), and visual disturbances (n = 1) were the reasons why the 4 other patients who experienced side effects stopped treatment; these events were not consid ered to be treatment related. Nine other patients were not available at 6 months because they were lost to follow-up (n == 4) or they refused their sec ond clinical and urodynamic pressure-flow study evaluation (n = 5). Sixty patients, of whom 30 (50%) were classified as patients with BOO, were evaluated clinically and urodynamically before and after 6 months (median 28 months; range 17 to 45 weeks) of treatment.
The mean variables listed in Table I were com pared between the group that continued taking terazosin for 6 months and the group that stopped taking terazosin before 6 months. Patients who stopped terazosin before 6 months were statisti-cally significantly younger (mean age ± SD 58 ± 9 years) when compared with patients who con tinued taking terazosin up to 6 months (64 ± 8 years; P <0.01). The mean bladder capacity in those who discontinued terazosin was higher (458 ± 1 2 5 mL) when compared with those who con tinued treatment up to month 6 (403 ± 136 mL; P = 0.03). When comparing the mean Pvoidm in (23.3 ± 15 versus 32.3 ± 18.8 cm H20; P = 0.01), the mean URA (29.3 ± 14.1 versus 38.6 ± 21.1 cm H20; P = 0.04), and the mean lin-PURR cat egory (1.9 ± 1.4 versus 2.7 ± 1.5; P = 0.02) be tween those who stopped terazosin treatment and those who continued it for 6 months, respectively, the mean values of those who stopped were sig nificantly smaller, indicating that patients without BOO had a higher likelihood of stopping terazosin for various reasons before 6 months. Table II outlines the mean symptom scores and mean urodynamic variables at baseline and after 6 months of treatment of the 60 patients who com pleted terazosin treatment for 6 months; the pa tients are divided into two subgroups, those with and without BOO. Also indicated in this table is the comparison of the changes in these variables between the groups with and without BOO. Mean total IPSS improved significantly in both groups: from 19.7 to 10.6 in the group without BOO and from 20.1 to 11.1 in the group with BOO (for both groups, P <0.01). The mean IPSS quality-of-life score improved significantly in both groups: from 4.1 to 2.0 in the group without BOO and from 4.1 to 2.3 in the group with BOO (for both groups, P <0.01). The mean symptom and quality-of-liferelated changes between the groups without and with BOO were not significantly different (P = 0.89 and P = 0.85, respectively). In patients with out BOO, mean free Qmax improved significantly by 4.4 mI7s (P <0.01), mean free voided volume increased by 24 mL (P = 0.52), and mean free residual volume did not change significantly (P = 0.24). In the patients with BOO, mean free Qmax improved significantly by 1.6 mL/s (P = 0.04), mean free voided volume decreased by 32 mL (P = 0.15), and mean free residual volume decreased significantly from 110 to 59 mL (P -0.03). The mean change of free Qmax was significantly higher in the group without BOO when compared with the group with BOO (P = 0.01). This could have been related to an increase of voided volume of 24 mL in the group without BOO and a decrease of voided volume of 32 mL in the group with BOO. The statistically significant difference in the change of free Qmax between the groups with and without BOO was evaluated further. Small im provements in free Qmax (10% or more from base line) were found significantly more frequently in patients without BOO (77%) than in patients with BOO (48%) (P = 0.02). This higher number of patients with a small improvement of free Qmax could be related to an increase in free voided vol ume in patients without BOO. Forty-seven percent of the patients without BOO had an increase of free voided volume of at least 50 mL, whereas of those in the group with BOO, only 14% had an increase of free voided volume of 50 mL or greater (P <0.01). When comparing the number of patients with larger improvements of free Qmax (30% or 50% or more from baseline), there were no signif icant differences between the two groups. Sixty per cent of the patients without BOO and 41% of the patients with BOO had an increase of free Qmax of 30% or more from baseline (P = 0.15), and 43% and 34%, respectively, had an increase of free Qmax of 50% or more from baseline (P = 0.49). The mean free voided percentage improved from 85% to 91% in the group without BOO and from 74% to 82% in the group with BOO; changes within and be tween these groups were not significant.
The evaluation of the pressure-flow study vari ables urod Qmax, PdclQmax, Pvoidmin, Atheo, URA, and lin-PURR in the patients with BOO revealed statistically significant improvements of all mean variables after 6 months of terazosin treatment (Table II) . Significant changes of pressure-flow study variables in patients without BOO could not be detected, except for mean urod Qmax which improved significantly with 1.6 mL/s (P = 0.02). The mean bladder capacity in patients without BOO improved from 420 to 485 mL, which was statistically significant (P = 0.01). When evaluat ing the mean urodynamic changes between the groups with and without BOO, the changes for the variables urod voided percentage, PaetQmax, Pvoidmin, URA, and lin-PURR were significantly higher in the group with BOO. In Figure 1 , the improvements of PdetQmax and total IPSS are plot ted for each patient who completed 6 months of treatment. The patients with BOO tended to have a larger urodynamical improvement when com pared with patients without BOO. However, the symptomatic improvement is in the same range in both groups.
In Table III , the mean changes in symptoms, qual ity of life, free uroflow variables, and urodynamic variables are compared between the group of pa tients who improved urodynamically (that is, the group that had a lin-PURR decrease of 1 point or more on the Schafer nomogram) and the group who did not. Only the changes in the inter-related uro dynamic variables PdetQmax, Pvoidmim URA, and lin-PURR were significantly higher in the group that improved urodynamically. The mean changes in symptoms, quality of life, and free uroflow variables were not significantly different between those who improved urodynamically and those who did not.
TA BLE II. Mean characteristics, at baseline and after 6 months of terazosin treatment, for the 60 patients who completed the second urodynamic evaluation, divided into subgroups of patients, with and without bladder outiet obstruction (standard deviation in parentheses) * After 6 months, 54 of 93 patients (58%) contin ued terazosin treatment. The others were treated with transurethral microwave thermotherapy (n = 4), transurethral laser ablation of the prostate (n = 9), other medication (n = 7), or unknown pro cedures or medications (n = 4), or they were fol lowed with the watchful waiting policy (n = 15).
COMMENT
During the World Health Organization interna tional consultation on BPH in 1993, it was advised that, if obstruction is the end point of the study, pressure-flow studies before and after treatment should be used in the evaluation of new therapies. 16 Pressureflow studies enable us to investigate the relationship between subjective efficacy of treatment and objective voiding parameters. Moreover, the use of pressureflow studies may help to select patients for a given treatment; therefore, dropout and overtreatment per centages may decrease considerably.11, 17 With respect to the efficacy of terazosin in the group with BOO, we showed that all mean values of PdetQmax, Pvoidmin, Atheo, and URA improved significantly after 6 months of treatment with ter azosin. From a theoretical viewpoint, the mecha nism of voiding using an alphai-adrenergic blocker is changed toward better outlet distensibility during voiding; thus, it becomes more effi cient. The first effect of a decrease in outlet ob struction is presumably a change in the balance of bladder outlet and contraction toward a lowerpressure micturition with improved efficacy. The oretically, the increase in Qmax might not be as high as may be expected, which may be partly at tributed to a decrease in Pj^Qmax. More efficient voiding can also be shown by lower post-void re sidual volumes, but this could not be demon T A BLE III.
Comparison of the changes after terazosin treatment for 6 months between the group that improved urodynamicaiiy (Iin-PURR decrease of a t least 7 point) and the group that did not (standard deviation in parentheses)
Patients Abbrcvifliions as in Tabic I. strated by our patients; they had a low mean re sidual volume of 59 mL with a high standard deviation of 99 mL. A significantly larger Athe0, to gether with a significant decrease in Pvoidmin, in dicates that terazosin has relaxed the bladder out let so that more efficient voiding can occur.
In the patients without BOO, statistically signif icant changes of urodynamic variables could not be shown, except for free Qmax, urod Qmax, and bladder capacity. When evaluating the present study, we have to realize that this study is a non controlled one, so we have to be careful in drawing far-reaching conclusions with respect to efficacy. Exact quantification of the urodynamic effect of treatment is only possible with a double-blind, pla cebo-controlled study. This is mainly due to a large placebo effect that exists in patients treated with an alpha!-blocker such as terazosin. In a large randomized, double-blind study, Roehrborn et a l 18 showed a 7.6-point improvement in symptom score on the IPSS scale in the terazosin-treated group, whereas in patients treated with a placebo, symptom score improved by only 3.7 points. The improvements in free Qmax were an increase of 2.2 mL7s in the terazosin-treated group and an in crease of 0.8 mL/s in the placebo-treated group.18
At baseline, patients with BOO had a signifi cantly different voiding mechanism, with lower voided percentages and lower maximum flow rates when compared with the group without BOO (Ta ble I). Because terazosin treatment improves the obstruction classification, some patients will shift from the group with BOO to the group without BOO, and this could result in a favorable improve ment of free Qmax.
In the present study, dropout percentages were relatively higher than those reported in the liter ature. Lepor8 reported that, of 494 patients en rolled in a 42-month, open-label, multicenter study of terazosin, 213 (43%) withdrew prema turely; 55 (11%) because of lack of effectiveness, 96 (19%) because of adverse events, and 62 (13%) because of administrative reasons. It could be that the 38% dropout rate in the present study (37 of 97 patients dropped out before 6 months) is rela tively higher because we offered patients with moderate symptoms or patients who are bothered by their symptoms the choice between an alphaiblocker or other minimally invasive therapies. With a wide variety of minimally invasive treat ment options, patients and urologists may more easily change their original treatment decision, compared with a situation where, after alphaiblocker treatment, the only options are watchful waiting or prostatectomy.
Patients without BOO were more prone to early dropout for various reasons when compared with patients with BOO. In patients with a lin-PURR of 0 or 1, the poor urinary stream is caused by a hypoactive detrusor muscle. These patients benefit little from transurethral resection of the prostate.11 It could be that the unobstructed patients are also less likely to benefit from alphai-blockers. This may be consistent with the assumption that it is unlikely that the detrusor function is improved by these drugs.
Our study design may be criticized for lack of a placebo control group and for potential selection bias. However, the mean changes of peak flow rates and symptom scores observed in this open-label study were comparable to the data from a randomized study.19 Earlier studies have indicated that the expected improvement of mean free Qmax after 6 months of treatment with terazosin is be tween 2.4 and 3.1 mL/s. 8, 9, 18, 19 In our study, the mean improvement of free Qmax in the total group of patients was 3.0 mUs. One may question the clinical relevance of a 3.0 mUs improvement of free Qmax. This study indicates that, besides the improved free Qmax, more variables may change after terazosin therapy. In the present study, unob structed patients had a statistically significantly in creased bladder capacity. Patients with BOO had a statistically significantly decreased residual vol ume. As a result of these changes, another mictu rition pattern may develop that could result in a significant improvement of the IPSS, especially when taking into account that the questions of the IPSS questionnaire are concerned with bladder emptying, frequency, intermittency, urgency, noc turia, weak stream, and hesitancy. All of these symptoms may improve as a result of improved free Qmax, bladder capacity, or residual volume.
When comparing the changes after 6 months of therapy between the patients with and without BOO, the changes in symptoms and quality of life were not significantly different (Table II ). An im provement of free voided volume of 50 mL or more occurred significantly more frequently in the group without BOO. A larger voided volume in the group without BOO could result in a higher num ber of patients with slight improvements in free Qmax. When comparing the free voided volumes with the free Qmax, using the Liverpool nomo grams, it appeared that the values of the first void ing in the group without BOO-a voided volume of 286 mL and a free Qmax of 11.4 m u's-cor respond with the 5tli percentile whereas the values of the second voiding-a voided volume of 311 mL and a free Qmax of 15.9 mL/s-correspond with the 17th percentile of the healthy males in vestigated.20 For the group with BOO, the values of the flows correspond with the 5tli and 10th per centile for the first and the second voiding, re spectively. This indicates that, despite the different voided volumes, the free Qmax increases, probably as a result of therapy. When we evaluated the number of patients with greater improvements in free Qmax, there was no significant difference be tween groups with and without BOO, which dem onstrates that, in our patients without BOO, sta tistically significant improvements in free Qmax were not confirmed by significant improvements of urodynamic variables. Significant changes in urodynamic variables were only shown in the group with BOO. This finding suggests that the way we analyze efficacy in most pharmacotherapy studies for BPH (that is, improvements in symp toms and small improvements of Qmax) does not depend on the urodynamic mechanism of action. Therefore, we cannot recommend the use of pressure-flow studies in the selection of patients for terazosin treatment in daily urologic practice be cause the changes of symptoms and quality oi life between the groups with and without BOO were not significantly different. Moreover, the number of patients with improvements of free uroflow of at least 30% appeared not to be significantly dif ferent between groups with and without BOO. Hence, it seems more useful and certainly less ex pensive and less invasive to start alphai-blocker therapy if, on clinical grounds, the urologist con siders the patient to be a candidate for alphaiblocker therapy and to continue therapy in those who are satisfied.
However, it is unknown what the long-lasting effect of BOO on the bladder is for patients who are satisfied with their treatment but who remain urodynamically obstructed. Do they have a higher likelihood of developing complications in the long term, such as obstructive nephropathy, urinary re tention, infection, bleeding, bladder stones, or other complications that adversely affect their well-being? Is there a difference in the probability of developing complications when compared with patients without BOO? Further follow-up and more prospective, well-controlled investigations are necessary to provide the still-lacking infor mation on the long-lasting effects and complica tions of pharmacologic treatment.
CONCLUSIONS
We have shown that a stratified analysis, based on the urodynamic classification of BOO, provides insight into the working mechanism of terazosin in patients with and without BOO. Patients with a hypoactive detrusor muscle may be more prone to drop out early when compared with patients who have a normal detrusor function. We also showed that after 6 months of terazosin treatment, the changes of symptoms and quality of life and the number of patients with improvements of free uro flow of 30% or greater appeared not to be signifi cantly different between the groups with and with out BOO, Therefore, we cannot recommend the use of pressure-flow studies in daily urologic prac tice if, on clinical grounds, the urologist considers the patient to be a candidate for alphai-blocker therapy. It seems more useful, and certainly less expensive and less invasive, to start terazosin ther apy for patients and to stop therapy in those who are not satisfied. In the dissatisfied patients, pressure-flow studies could be of help in selecting pa tients for more invasive treatments. In patients who are satisfied with their treatment, terazosin could be continued. However, because the long term complications of pharmacologic treatment in patients with BOO are not well known, we rec ommend to follow up these patients on a regular basis.
The authors have done an extensive urodynamic analysis of a group of men receiving terazosin therapy. A number of interesting points can be gleaned from this report: (1) not surprisingly, men with lower urinary tract symptoms have varying urodynamic findings; (2) the magnitude of response to terazosin cannot be predicted based on pretherapy pressure-flow evaluation; and, most interestingly, (3) the drop outs or discontinuation group tended to be younger, to have higher bladder capacities, and to not have bladder outlet ob struction (BOO),
There arc a number of methodologic questions that remain unresolved. Primarily, the population was highly select and not randomized. Although briefly noted by the authors, the primary concern is how many patients were screened. We know that 97 patients were enrolled, but how many were ex cluded and why? Given the enrollment period of more than 2 years, this relatively low number of patients suggests a po tential selection bias.
Second, the magnitude of response in this study is not con sistent with previously reported studies with terazosin. In pa tients without BOO, maximum flow (Qmax) increased 4.4 mL/s, more than twice that reported from larger multicenter trials using either terazosin or other alpha-blockers such as doxazosin or tamsulosin. In addition, one would think that patients with BOO would have a greater likelihood of increas ing Qmax than those without BOO. In this study, the exact opposite occurred. Although the authors' conjecture that this may be due to higher voided volumes in the group without BOO, the magnitude of response is still extraordinary.
Third, the dropout rate was 29% at 6 months. This also represents a higher rate than other reported clinical studies using alpha blockade. In addition, we reported that more than 70% of patients were on alpha-blockers at 2 years.1
Pressure-fiow evaluation is an important instrument used in the diagnosis, management, and follow-up of urologic clisorders that affect the lower urinary tract. Although the role of routine urodynamic evaluation in lower urinary Lract symp toms in men is in question, pressure-flow studies remain the best objective test for BOO. Various investigators have re-* ported an imprecise relationship between subjective parame ters such as symptoms and urodynamic findings. In part, this may be secondary to different methods of performing uro dynamic studies among investigators, as well as defining the most appropriate parameters of obstruction. In this study, a linear passive urethral resistance relation of less than 3 was considered urodynamic evidence of no obstruction. Should this parameter be the reference standard? Even urodynamic advocates cannot agree on what should be the parameter used to diagnose obstruction. For urodynamics to have widespread clinical usefulness, parameters of measurement should (1) ideally correlate with symptoms; (2) delineate which patients are at risk if left un treated; and (3) predict the need for therapy and success of therapeutic options designed to alleviate outlet obstruction. The challenge of those who advocate pressure-flow evaluation prior to instituting therapy is to meet these aforementioned criteria successfully. In this regard, as recommended by the authors, it seems prudent, economical, and clinically reason able to institute a trial of alpha-blockade in lieu of sophisti cated pressure-flow evaluation. 
REPLY BY THE AUTHORS
There is no dispute that there are methodologic questions when comparing the results of noncontrolled studies. A large part of the differences between noncontrolled studies can be explained by selection of patients or by using other techniques of measurement. Our group of patients may be a specifically selected group of patients. In our hospital, when the patient experiences moderate symptoms or is bothered by his symp toms, treatment with an alpha i-blocker is recommended in addition to other minimally invasive therapies, such as trans urethral microwave thermo therapy or laser treatment of the prostate. With such a wide variety of treatment options, the group of patients who choose alphai-blocker treatment may be different when compared with the situation where the only other treatment options are watchful waiting and prostatec tomy. Furthermore, patients and urologists may more easily change their original treatment decision and, hence, a larger number of patients will drop out from the study.
In patients without bladder outlet obstruction, the magni tude of improvement of mean free maximum flow (4.4 mL/s) is higher than the previously reported 2.4 to 3.1 mlVs. How ever, the 95% confidence interval of this improvement indi cates that, in this group of patients, the true mean difference lies between 2.7 and 6.2 mL/s, and these values show an over lap with previously reported numbers. Moreover, when the maximum flow during urodynamic investigation was taken into account, the mean improvement of maximum flow was not significantly different between the patients with or with out obstruction despite a larger bladder capacity (P = 0.06) in patients without bladder outlet obstruction. This indicates that the large improvement in maximum flow in patients without bladder outlet obstruction, as shown in our study, is consistent with previously reported studies.
An imprecise relationship between symptoms and urody namic findings was recently reported by Ezz el Din et al. 1 who, in one center, evaluated the relationship between urodynamic findings and the International Prostate Symptom Score and specific questions in 803 patients. They concluded that these methods measure different aspects of the clinical condition that should be viewed separately in the evaluation and treat ment decision of the patient presenting with lower urinary tract symptoms. Witjes et al. 2 have recently shown that uro dynamics and symptom scores are unable to delineate which patients are at risk when left untreated, Patients with severe obstruction on urodynamics did not worsen in the short term; on the contrary, they were more likely to improve than to deteriorate urodynamically. Symptoms in this specific group of patients did not change significantly, confirming the dis crepancy between subjective and objective data.
Because earlier studies have indicated that inclusion of pressure-flow data in the preoperative evaluation and patient selection for interventional therapies such as transurethral re section of the prostate and transurethral microwave thermotherapy may improve the overall clinical results,3,4 it is our opinion that symptoms alone should not be used as the main indication for deciding on the appropriate minimally invasive or invasive treatment options.
We agree with Dr. Kaplan that, with future analyses of stud ies such as the ICS-'BPH* study,5 we may be able to provide vital information on the relative potential of symptoms and urodynamic and other clinical parameters to predict a favor able response to current and innovative treatments. 
